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Purpose: To develop and validate a user-friendly spiked plasma method for the extraction of diclofenac 
potassium that reduces the number of treatments with plasma sample, in order to minimize human error. 
Method: Instead of solvent evaporation technique, the spiked plasma sample was modified with H2SO4 
and NaCl, respectively, and then the drug was extracted after vortexing the sample with acetonitrile as 
precipitating agent. The separation of diclofenac potassium and internal standard (ketoprofen) was 
achieved at preset conditions: 5 µm ODS Hypersil C-18 (4.0 mm x 250 mm) column, eluted with 50% 
acetonitrile in water (v/v) as mobile phase containing ammonium acetate and triethylamine (TEA), at a 
flow rate of 1 mL min
-1
. 
Results: The peaks of the drug and internal standard (I.S.) were resolved at 14 ± 1 min and 7 ± 1 min, 
respectively. The calibration curve and linearity were determined over the concentration range of 0.25 to 
40 µg mL
-1 
and they were linear (r
2
 = 0.9991 and 0.9982, respectively). The accuracy was > 81.32 %. 




respectively, while the recovery 
range for diclofenac potassium and ketoprofen was more than 79 and 85 %, respectively. The absolute 
average difference of 0.18 between the observed concentrations for intra- and inter-day studies 
indicated that the sample was stable for over one month. 
Conclusion: The proposed method may be applied to routine bioanalysis, particularly for NSAIDs, due 
to its high sensitivity, specificity, repeatability, reproducibility, robustness and ruggedness. 
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INTRODUCTION 
 
Diclofenac potassium is a faintly yellowish 
white to light beige, virtually odorless, slightly 
hygroscopic crystalline powder. It is freely 
soluble in methanol, soluble in ethanol and 
water, and practically insoluble in chloroform 
and in dilute acid. The n-octanol/water 
partition coefficient is 13.4 at pH 7.4 and 
1545 at pH 5.2. It has a single dissociation 
constant (pKa) of 4.0 ± 0.2 at 25°C in water 
[1]. Diclofenac potassium (Diclo-K) is a 
substituted phenyl-acetic acid derivative and 
widely used in the management of many 
inflammatory conditions [2-3]. It also has 
analgesic and antipyretic actions. In spite of 
its pharmacological importance, relatively few 
studies are known to explain analytical 
quantification of diclofenac potassium in 
human plasma.  
 
HPLC is a powerful tool for analyzing small 
analytes such as drugs in biological samples. 
However, analysis of analytes present in 
matrices such as plasma requires well-
designed sample preparation procedures 
such as protein precipitation, centrifugation, 
extraction and filtration that can introduce 
experimental errors and ultimately reduce 
precision and accuracy of measurement [3-
4]. An attractive approach would be to reduce 
the number of treatments in sample 
preparation procedure in order to minimize 
human and non-human errors. Reverse 
phase high performance liquid 
chromatography (RP-HPLC), a bonded 
phase chromatographic technique, uses 
water as a base solvent. Separation based 
on solvent strength and selectivity also may 
be affected by column temperature and pH. 
In general, the more polar component 
(diclofenac potassium) elutes faster than the 
less polar one [4]. In the pH range 2 - 8, RP-
HPLC resolves polar components efficiently 
[5]. 
 
The aim of this work was to develop a simple, 
accurate, reproducible and sensitive method 
for the determination of diclofenac potassium 
in human plasma using rapid, convenient and 
simple liquid-liquid extraction and reverse 
phase HPLC method based on UV-visible 






All the reagents used were of analytical 
grade. Diclofenac potassium was donated by 
PDH Pharmaceuticals Pvt Ltd, Lahore, 
ketoprofen by Sanofi Aventis Limited Karachi, 
Pakistan. Acetonitrile, methanol, ammonium 
acetate, triethylamine (TEA), sodium chloride, 
sulphuric acid and ortho-phosphoric acid 85 
%v/v were obtained from Merck, Germany. 
HPLC grade water was obtained using a 
water distillation appratus (model, IM-100, 
Irmeco GmbH, Germany) and filtered, prior to 
use, through a vaccum filter assembly 
(Sartorius Goettingen, Germany) containing a 




HPLC (Perkin Elmer, Series 200, USA) with 
TCNav software, consisted of a binary pump 
solvent delivery system, an ultraviolet-visible 
(UV-Vis) variable wavelength detector, 
integrator NCI 900 was used. Samples were 
introduced into a Rheodyne 20 µL fixed-loop 
injector with a 50 µL glass syringe. 
Chromatographic separation was performed 
on a 5 µm particle size, 4.0 mm x 250 mm 
ODS Hypersil C18 stainless steel analytical 
column (Thermo Electron Corporation, UK). 
All solvents were degassed with a sonicator 
(Elma D78224, Germany) and pH were 
checked with a pH meter (Inolab, Series 
WTW, Germany) prior to use. 
 
Preparation of mobile phase 
 
To prepare 1 L of mobile phase, 500 mL of 
HPLC grade water was added to 500 mL of 
acetonitrile. Freshly prepared 0.1 M 
ammonium acetate (2 mL) and 100 µL TEA 
were added, consecutively, to the mixture. 
This order of mixing was strictly maintained 
throughout the study. The pH of the mobile 
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phase was adjusted to 3.0 using 
orthophosphoric acid. The mobile phase was 
prepared daily and was not recycled during 
use. 
 
Preparation of stock solution 
 
Stock solution of diclofenac potassium was 
freshly prepared in 50% (v/v) aqueous 
acetonitrile to give a final concentration of 1 
mg mL
-1
 (1000 µg 1000 µL
-1
). Working 
solutions of diclofenac potassium were 
prepared in 50% (v/v) acetonitrile by 
appropriate dilutions to give appropriate 
concentrations of 0.05, 0.1, 0.25, 0.5, 1.0, 
2.5, 5.0, 10, 20 and 40 µg mL
-1
. All the 
solutions were stored at -20 
0
C and protected 
from light. 
 
Stock solution of the internal standard 
(ketoprofen) was prepared with 50% (v/v) 
acetonitrile to give a concentration of 1 mg 
mL
-1
 (1000 µg 1000 µL
-1
) and then further 




Spiked plasma method 
 
The modified method [7,8] involved acidifying 
500 µL of plasma sample, containing 20 µL of 
Diclo-K and 50 µL of 250 µg mL
-1
 ketoprofen 
(I.S), with 500 µL of 1.74 M sulphuric acid. 
The plasma sample was modified with 20 µL 
of 3M NaCl and vortexed for 1 min [9,10]. 
Acetonitrile (500 µL) was added and vortexed 
for 30 s. The order of mixing was maintained 
throughout the study. The resultant mixture 
was centrifuged at 3000 rpm for 10 min. The 
supernatant was separated in Eppendrof 
tubes. An aliquot (20 µL) of this supernatant 
was chromatographed. 
 
Preparation of standard curve 
 
A standard curve was prepared by spiking 
500 µL plasma samples with 20 µL of one of 
the working solutions prepared above to 
produce calibration curve points equivalent to 
0.05, 0.1, 0.25, 0.5, 1.0, 2.5, 5.0, 10, 20 and 
40 µg mL
-1
of diclofenac potassium. 
Each suppernatant (20 µL) was injected with 
a 50 µL HPLC syringe and absorbance was 





Recovery was determined by comparing the 
values of the peak area of spiked plasma and 
its relevant solution using Eq 1. 
 
% Recovery = (Diclo-K ext/I.S)/ (Diclo-Knon-
ext/I.S) x 100 ……………………………… (1) 
 
 
where Diclo-K ext/I.S = area ratio of extracted 
diclofenac potassium to ketoprofen, and  
Diclo-Knon-ext/I.S = area ratio of solution of 




The method was validated in accordance with 
European Medicines Evaluation Agency 
(EMEA) guidelines [11] on validation of 
bioanalytical methods. General tests 
performed were: recovery, accuracy, 
precision, reproducibility, linearity, specificity, 





To evaluate the specificity of the developed 
method, placebo and appropriate test sample 
(spiked plasma) were run in triplicate on 
HPLC the preset conditions and the results 
compared, statistically. 
 
Linearity of the calibration line/range 
 
The calibration plots for the analyte in plasma 
were prepared by spiking drug-free plasma 
with standard stock solutions to yield 
concentrations of 0.25 - 40.0 µg mL
-1 
for 
diclofenac potassium. The linearity among 
nominal concentrations and observed peak 
area ratio was calculated by least squares 
method using regression line. 
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Accuracy and bias 
 
Accuracy and bias were determined for the 
developed method by performing 
measurements in consecutive and non-
consecutive sequences. For single analyte 
detection, the linearity was determined within 
the range of 50 – 150 % or 60 – 140 % or 80 
–120 % of the target concentration. Accuracy 
was calculated as in Eq 2. 
 
Accuracy (%) = (CObs. Mean/ CNom) x 100  ……… (2) 
 
Experimental errors in the test were 
determined using the values of standard 
deviation (SD) and standard error mean 
(SEM) while the accuracy of the results in 
consecutive and non-consecutive fashion 
was defined by values of the 95 % 
confidence of interval (95% CI) at lower (L) 




It was desirable to have an injection precision 
in terms of relative standard deviation (RSD). 
The precision of the method was defined with 
the existence of the results in range, i.e., 0 - 
10 [15-18]. The results of the developed 
method were validated by inter-day precision 
after one month. 
 
Limits of detection (LOD) and Quantifi-
cation (LOQ) 
 
The LOD for extracted diclofenac potassium 
from spiked plasma sample was measured at 
signal to noise (S/N) ratio of 2:1 with 
precision and accuracy. To determine LOD 
and LOQ, the plasma samples were 
chromatographed with descending order of 
the spiked concentrations of analyte. Based 
on the relative standard deviation (RSD) 
obtained, the LOQ was subsequently 
validated by replicate analysis (≥≥ 6) of 
samples prepared around this concentration. 
The LOD was taken as 0.2 x LOQ [19] and 
validated by comparing the known low 




First, this method was implemented for the 
extraction of diclofenac potassium. 
Thereafter, it was applied to extract 
ketoprofen as well. The peak areas were 
noted for each concentration under preset 
conditions shown in Table 1. 
 
Table 1: Optimal chromatographic conditions 
 
The recovery values (mean ± SEM) of 
diclofenac potassium and ketoprofen were 
98.09 ± 5.42 and 104.5 ± 6.76, respectively. 
Bias of the results are shown in Table 2. 
 
Table 2: Recovery data for diclofenac potassium 














0.25 85.54 14.46 116.91 -16.91 
0.50 96.10 3.90 104.06 -4.06 
1.00 126.51 -26.51 79.04 20.96 
2.50 141.77 -41.77 70.54 29.46 
5.00 99.54 0.46 100.46 -0.46 
10.00 94.58 5.42 105.73 -5.73 
20.00 95.60 4.40 104.61 -4.61 





Column 5 µm ODS Hypersil C-18 
(4.0 mm x 250 mm) 
Guard column Uniguard TEC 
Mobile phase 50 % acetonitrile (100 
mL) + 0.1 M ammonium  
acetate (2 mL) + TEA (10 
µL) 
Flow rate 1.0 mL min
-1
 
Detection wavelength 276 nm 
Sensitivity 0.2 AUFS 
Injection volume 20 µL 
Retention time of IS 7 ± 1 min 
Retention Time of 
drug 
14 ± 1 min 
Temperature Ambient 
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The selectivity of the developed method was 
good based on the fact that there was no 
interfering peak in the chromatograms (not 
shown) at the retention time of diclofenac 
potassium. Both drugs (diclofenac potassium 
and ketoprofen, i.e., IS) were separated 
sufficiently at 14 ± 1 min and 7 ± 1 min, 
respectively. The calibration equation (y = 
20132x – 1740, with R
2 
= 0.9991) indicated a 
high degree of linearity as well as specificity 
of the method. At lower concentrations of 





% recovery of the sample was in a 
wider range thus indicating lower accuracy of 
the results due to sensitivity of the HPLC 
method at lower concentrations as shown in 
the Table 3. 
It was observed that the accuracy of the 
results for developed method was better for 
higher concentrations than for lower 
concentrations of the drug as shown in Table 
3. Precision was considered with intra- and 
inter-day performance of the developed 
method, as shown in Tables 4 and 5. 
 
All the results were within the defined range 
except for the lower concentration, i.e., 0.25 
µg mL
-1 
in intra-day study. Inter-day statistics 
also showed the stability of the extracted 
sample at -20 ºC. The LOD was 0.05 µg mL
-1
. 
The quantifiable concentration for diclofenac 
potassium in biological sample was 0.25 µg 
mL
-1 
under the stated HPLC conditions. 
 






0.25 0.50 1.00 2.50 5.00 10.00 20.00 40.00 




0.43 0.67 0.93 2.03 4.60 10.37 20.00 39.90 
SD 0.12 0.15 0.15 0.21 0.20 0.21 0.00 0.17 
SEM 0.07 0.09 0.09 0.12 0.12 0.12 0.00 0.10 
95% CI (L) 0.15 0.29 0.55 1.52 4.10 9.85 20.00 39.47 
95% CI (U) 0.72 1.05 1.31 2.55 5.10 10.88 20.00 40.33 
Bias 0.18 0.17 -0.07 -0.47 -0.40 0.37 0.00 -0.10 
Accuracy (%) 173.32 133.34 93.33 81.32 92.00 103.70 100.00 99.75 
 
Table 4: Intra-day statistics for diclofenac potassium 
 
Nominal conc. (µg 
mL
-1
)    





0.33 0.57 0.93 2.13 4.70 10.67 19.80 39.93 
SD 0.12 0.06 0.06 0.06 0.17 0.50 0.20 0.12 
SEM 0.07 0.03 0.03 0.03 0.10 0.29 0.12 0.07 
95% CI (L) 0.05 0.42 0.79 1.99 4.27 9.42 19.30 39.65 
95% CI (U) 0.62 0.71 1.08 2.28 5.13 11.92 20.30 40.22 
RSD 34.65 10.19 6.19 2.71 3.69 4.72 1.01 0.29 
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Table 5: Inter-day statistics for diclofenac potassium 
 




0.25 0.50 1.00 2.50 5.00 10.00 20.00 40.00 




0.26 0.54 1.06 2.50 5.20 10.65 20.00 40.30 
SD 0.02 0.04 0.03 0.04 0.10 0.64 0.00 0.21 
SEM 0.01 0.02 0.02 0.02 0.06 0.37 0.00 0.12 
95% CI (L) 0.22 0.45 0.99 2.40 4.94 9.05 20.00 39.78 





From the recovery data, the developed 
method is suitable for diclofenac potassium 
and ketoprofen. There were neither 
overlapping nor interfering peaks at the 
retention times of the drugs so it was 
presumed that all the plasma proteins 
precipitated efficiently during the plasma 
treatment process. Thus this reduced sample 
processing time. Although there was variation 
in bias this may be reduced by treating the 
samples more carefully during the extraction 
process. The mobile phase used in this work 
was so simple and economical; so also was 
the extraction procedure which was short in 
duration. Thus, the chances of column 
damage and degree of human errors were 
minimal. Recovery of both drugs (diclofenac 
potassium and ketoprofen) in the different 
assays under the same pre-set conditions 
may indicate the suitability of the developed 
method for NSAIDs and its analogs. 
Regarding the stability of the drug in human 
plasma, the intra- and inter day statistics 
were favourable. The use of sulphuric acid 
and sodium chloride was critical to the 




During sample pretreatment, the following 
precautionary measures must be followed: 
(a) Molar solutions of NaCl and H2SO4 that 
24-h old must not be used. It was found that 
old solutions did not precipitate plasma 
proteins efficiently. (b) The solutions must be 
accurately prepared at the exact molar 
concentrations; otherwise, there will be 
improper extraction of the drugs from the 
plasma. (c) Do not inject spiked plasma if it is 
turbid. (d) Be careful regarding the order of 
mixing. Any change in mixing order may 




The proposed method may be applied to 
routine analysis of diclofenac potassium due 
to its high sensitivity, specificity, repeatability, 
reproducibility, robustness and ruggedness. 
The method is also applicable to ketoprofen 
which was used as the internal standard (IS). 
The extraction procedure is especially time-
saving for in vivo analysis of NSAIDs. 
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